在现实生活中的癌症患者队列中，对第四次SARS-CoV-2疫苗的细胞和体液反应

IF 0.4 Q4 ONCOLOGY

memo - Magazine of European Medical Oncology Pub Date : 2023-10-13 DOI:10.1007/s12254-023-00916-y

Julia M. Berger, Pia Gattinger, Maximilian J. Mair, Anna S. Berghoff, Rudolf Valenta, Matthias Preusser

{"title":"在现实生活中的癌症患者队列中，对第四次SARS-CoV-2疫苗的细胞和体液反应","authors":"Julia M. Berger, Pia Gattinger, Maximilian J. Mair, Anna S. Berghoff, Rudolf Valenta, Matthias Preusser","doi":"10.1007/s12254-023-00916-y","DOIUrl":null,"url":null,"abstract":"Summary This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"35 1","pages":"0"},"PeriodicalIF":0.4000,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer\",\"authors\":\"Julia M. Berger, Pia Gattinger, Maximilian J. Mair, Anna S. Berghoff, Rudolf Valenta, Matthias Preusser\",\"doi\":\"10.1007/s12254-023-00916-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed.\",\"PeriodicalId\":18379,\"journal\":{\"name\":\"memo - Magazine of European Medical Oncology\",\"volume\":\"35 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"memo - Magazine of European Medical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12254-023-00916-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"memo - Magazine of European Medical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12254-023-00916-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究评估了恶性疾病患者对第四剂SARS-CoV-2疫苗的细胞和体液反应。尽管在大多数接受积极治疗的患者中明显存在体液、细胞或联合反应的明确适应症，但观察到患者体内和患者间反应模式的高度异质性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer

Summary This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

memo - Magazine of European Medical Oncology ONCOLOGY-

CiteScore

1.80

自引率

16.70%

发文量

期刊介绍： memo is the Official Journal of the Central European Cooperative Oncology Group (CECOG) and The Austrian Society of Haematology and Oncology (OeGHO). The focus of the journal "magazine of european medical oncology – memo" is to offer a professional review on current research and development in the field of hematology and oncology relevant for daily practice. Therefore, memo includes editorials and comments, peer-reviewed original reports, short reviews, case reports and controversies, articles explaining the biology of neoplasia and congress reports including qualified comments. As a European journal memo aims at highlighting the local peculiarities of various regions and at being a forum for the presentation of ongoing clinical and basic research.